Top Markets
#1 ADO Protocol ADO Protocol +193.44%
#2 Islamic Coin Islamic Coin +155.40%
#3 GoPlus Security GoPlus Security +43.47%
#4 GAIB AID GAIB AID +24.67%
#5 Casper Network Casper Network +15.03%
#6 Verus Coin Verus Coin +13.64%
#7 SkyAI SkyAI +13.54%
#8 Starpower Starpower +12.35%
#9 o1.exchange o1.exchange +11.59%
#10 Ontology Gas Ontology Gas +10.82%
Coin of the day
ADO Protocol ADO Protocol
Settings
Language
ENGLISH
Currency
USD
Theme
TME Pharma N.V. TME Pharma N.V.

TME Pharma N.V.

ALTME
Rank in Stocks #33514
TME Pharma N.V., a biopharmaceutical company in the clinical development stage... TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Share Price
$0.07603255
Market Cap
$7.16M
Change (1 day)
0.16%
Change (1 year)
-40.95%
Country
DE
Trade TME Pharma N.V. (ALTME)

Category

Healthcare
Revenue for TME Pharma N.V. (ALTME)
Revenue in Aug 2026 TTM: 0
According to TME Pharma N.V. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for TME Pharma N.V. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE